Last reviewed · How we verify
YM060
YM060 is a selective and potent kappa opioid receptor antagonist.
YM060 is a selective and potent kappa opioid receptor antagonist. Used for Chronic pain.
At a glance
| Generic name | YM060 |
|---|---|
| Also known as | ramosetron, Irribow, ramosetron, Irribow, Ramosetron, ramosetron, |
| Sponsor | Astellas Pharma Inc |
| Drug class | kappa opioid receptor antagonist |
| Target | kappa opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 3 |
Mechanism of action
YM060 works by blocking the kappa opioid receptor, which is involved in pain modulation and other physiological processes. This action is thought to contribute to its analgesic effects. However, the exact mechanisms underlying its therapeutic effects are not fully understood.
Approved indications
- Chronic pain
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
Key clinical trials
- Analgesic Efficacy of Maxigesic in Breast Cancer Surgery (NA)
- Special Drug Use Surveillance of Irribow in Female Patients
- The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting (NA)
- Acupuncture for Postoperative Nausea and Vomiting in Patients Undergoing Colorectal Surgery (NA)
- The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence (PHASE2, PHASE3)
- 5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS) (NA)
- The Effect on Anxiolytics With Type of Antiemetic Agents on Postoperative Nausea and Vomiting in High Risk Patients
- Ramosetron on Late PONV (Postoperative Nausea and Vomiting) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |